As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

As­traZeneca is shelv­ing an IL-23 an­ti­body that’s been through a wind­ing jour­ney around phar­ma — in­clud­ing stops at Am­gen and Al­ler­gan — and putting an end to Phase II and III tri­als test­ing the drug for in­flam­ma­to­ry bow­el dis­ease.

“The de­ci­sion to dis­con­tin­ue brazikum­ab’s IBD de­vel­op­ment fol­lows a re­cent re­view of brazikum­ab’s de­vel­op­ment time­line and the con­text of a com­pet­i­tive land­scape that has con­tin­ued to evolve,” a press re­lease reads.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER